Goldman Sachs Reiterates Buy on Omron: Strong AI-Driven Demand, Restructuring Benefits Emerging

Overview

This report summarizes Goldman Sachs' earnings commentary and meeting notes on Omron (6645.T). The report argues that Omron’s Industrial Automation Business (IAB) is experiencing a notable demand recovery driven by strong AI-related capital expenditure, and the company is well-positioned through structural reforms to capture this upcycle. Despite market concerns about competitive pressure from Chinese rivals and supply chain bottlenecks, Omron has taken proactive steps in component procurement and maintains a solid market position in high-value segments. Goldman Sachs maintains a 'Buy' rating, believing the market underestimates Omron’s recovery potential and its long-term strategic value as a core player in data control.

Core views

Demand Side: AI Drives Real Growth. Omron confirmed a significant improvement in recent IAB demand, with approximately 60% of real demand driven by AI-related capital expenditure (e.g., rechargeable batteries for semiconductors and data centers), while the remaining 30–40% stems from new product launches and enhanced sales efforts leading to market share recovery. China shows strong performance in AI-related segments, and demand from Japanese specialty precision electronics (SPE) manufacturers is also recovering. Management emphasized that the current order acceleration reflects genuine end-demand rather than inventory restocking, and April results exceeded expectations—if this trend continues, FY3/27 guidance could be substantially surpassed. Supply Side: Well-Prepared Supply Chain with Smooth Cost Pass-Through. Facing risks of component shortages (e.g., memory and resins) and rising input costs, Omron has proactively secured necessary component supplies for all of FY3/27 and early FY3/28. The company stated it can effectively pass raw material cost increases downstream, limiting the risk of significant margin compression. In contrast, demand-side momentum shows no signs of slowing; the main risks lie on the supply side regarding procurement challenges. Competitive Landscape: Strong Position in China’s High-Value Segments. Addressing market concerns that Omron is losing share in China to domestic competitors like Inovance, the report highlights Omron’s continued strength in high-value segments such as semiconductors and rechargeable batteries. For example, at a major battery customer, Omron’s average share—covering components, software, and control technologies across manufacturing and upstream processes—exceeds 40%, reaching as high as 75% in certain steps. This ability to meet high-precision requirements across the entire workflow forms a competitive moat. Additionally, the traditional industrial machinery segment (70% of China sales) is shifting toward higher-value products due to rising safety standards, improving the overall product mix. Other Businesses: Healthcare Data Potential. While the Healthcare segment faces commoditization risks, the company plans to enhance value creation through data collected via sensing technologies. Its collaboration with JMDC is seen as essential to its long-term vision, and generative AI advancements could accelerate data utilization in healthcare, unlocking new business opportunities.

Analysis framework

Goldman Sachs combined a top-down industry cycle analysis with bottom-up validation of company-specific competitiveness. First, by decomposing order drivers (60% from AI Capex), it distinguished real demand from inventory cycles to assess demand sustainability. Second, it evaluated Omron’s supply chain resilience by comparing its proactive component locking strategy against industry-wide shortages. Finally, it used specific customer case studies (e.g., battery manufacturer share data) to challenge the market consensus on China competition, verifying Omron’s pricing power and customer stickiness in high-value segments. For valuation, an EV/EBITDA multiple approach was used, applying a premium versus the sector average to reflect Omron’s structural improvements and leadership in data control.

Methodology notes

• Valuation MethodEV/EBITDA valuation

  Valuation based on FY3/28E EV/EBITDA multiple

  The firm used Enterprise Value to EBITDA (EV/EBITDA) multiples for valuation, applying a sector average of 10x and granting a 20% premium due to Omron’s relative advantages to arrive at the target price. This method is commonly used for capital-intensive or high-depreciation manufacturing firms, as it better reflects operating cash flow generation.

• Industry/Market Analysis FrameworkSupply-demand framework

  Distinguishing Real Demand from Inventory Restocking

  The report analyzed order sources (AI Capex vs. inventory rebuilding) to conclude that the current upswing is driven by genuine end-demand, supporting the view that demand is sustainable rather than a short-term inventory-driven rally.

• Competition & Strategy FrameworkMoat / competitive advantage

  Customer Stickiness and End-to-End Capability in High-Value Segments

  Specific share data (40%–75%) demonstrates Omron’s irreplaceability in complex processes like battery manufacturing. This technology- and full-process-service-based advantage creates a moat against price-based competition.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Omron (6645.T)

  Direct beneficiary; increased AI capital expenditure drives demand for its industrial automation equipment and components

  Strengths

  Well-prepared supply chain (secured materials for FY3/27–28), stable share in China’s high-value segments, strong cost control and pricing power

  Weaknesses

  Healthcare business faces commoditization risk; conservative mid-term margin target (16%)

  Comparison

  Compared to other FA players, Omron is more proactive in addressing supply shortages and has not lost share in China’s premium segments as feared by the market

  Risks

  Slower-than-expected growth in solutions sales, weaker-than-expected execution in component procurement

Key data

• 12-Month Target Price7,400 JPYBased on FY3/28E EV/EBITDA of 10x with a 20% premium over sector average
• Current Share Price5,597 JPYAs of May 28, 2026 close
• Implied Upside32.2%Potential upside from current price to target price
• AI Capex Contribution to DemandApprox. 60%Share within IAB’s real demand
• IAB Mid-Term Operating Margin Target16%Set under SF2030 Phase 2 roadmap, below prior cycle peak of 18%
• FY3/27E Revenue ForecastJPY 86.7 billionGoldman Sachs forecast
• FY3/27E EPS286.0 JPYGoldman Sachs forecast, likely to exceed consensus

Impact & implications

The report argues that the market currently underestimates Omron’s earnings elasticity in this upcycle and its long-term strategic positioning in data control. With sustained AI investment, Omron can benefit from both near-term volume and pricing tailwinds and achieve structural margin improvements through ongoing reforms. For investors, Omron offers exposure to the AI hardware infrastructure boom while possessing defensive supply chain strengths. Its healthcare data initiatives also provide a second growth curve over the long term.

Risks

• Solutions sales growth in IAB weaker than expected
• Slower-than-expected expansion of IAB business in developed markets
• Unfavorable shift in business mix
• Ongoing shortages of key components (e.g., memory, resins) disrupting production
• Geopolitical uncertainties (e.g., Middle East) impacting macroeconomic conditions

What to watch

• Execution of key component (especially memory) procurement for FY3/27 and FY3/28
• Sustainability of orders and market share trends in China’s high-value segments (semiconductors, batteries)
• Whether IAB operating margin can structurally exceed the 16% mid-term target
• Progress and synergy realization from the JMDC collaboration on healthcare data utilization